2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Molecular Testing, Omics Technologies, Bioinformatics, Computational Biology, Emerging Technologies, Gene Editing, Profiling, Treatment Considerations, Combination Therapy, Biological Therapies, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Gene Therapy, Immunotherapy, Non-Biological Therapies, Chemotherapy, Artificial Intelligence (AI), Deep Learning, Machine Learning, Biological Processes, Pathogenesis, CHIP, Genomics, Immune Mechanism, Metabolism, Molecular Biology, Clinical Practice (Health Services and Quality), Clinical Guidelines, Diseases, Lymphoid Malignancies, Lymphomas, Plasma Cell Disorders, Measurable Residual Disease, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B Cell Lymphoma, T Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Fundamental Science, Translational Research, Clinical Research, Clinical Trials, Health Outcomes Research, Real-World Evidence, Study Population, Human, Adult, Elderly, Animal Model
PAPER

3498 Addition of tafasitamab (Tafa) to lenalidomide and rituximab (R2) shows activity in patients (pts) with molecularly defined high-risk relapsed or refractory follicular lymphoma (R/R FL): Results from a global, randomized, phase 3 study (inMIND)

Diana Alvarez Arias, Verena Passerini2, Taehyung Kim, PhD3, Sarah Reinke4, Wolfram Klapper5, Philomena Colucci, MD, DO6, Haobo Ren7, Oliver Weigert, MD8
1 Incyte Corporation, Wilmington, Delaware, United States
2 University Hospital, LMU, Munich, Germany
3 Incyte Corporation, Wilmington, Delaware, United States
4 University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany
5 University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany
6 Incyte Corporation, Wilmington, Delaware, United States
7 Incyte Corporation, Wilmington, Delaware, United States
8 University Hospital, LMU, Munich, Germany

Background: The primary analysis of inMIND demonstrated a significant benefit of Tafa-R2 vs placebo (Pbo)-R2 in investigator-assessed progression-free survival (PFS) in pts with R/R FL, representing a 57% reduction in the risk of progression or death, with a safety profile as expected (Sehn, Lancet 2026). PFS benefit was observed across high-risk subgroups, including pts with progression of disease within 24 months (POD24), FLIPI 3-5, bulky disease, and refractoriness to prior chemoimmunotherapy (CIT) (Scholz, EHA 2026). With increased treatment options for R/R FL, there is a need to identify molecular subgroups of pts that benefit from novel treatments.

Methods: Comprehensive molecular profiling was performed on available baseline biopsies from pts enrolled in inMIND who had genetic data and evaluable RNA (molecular study cohort: n=204/548, 37%), using targeted DNA sequencing (DNAseq) of 252 genes and loci recurrently mutated in FL (n=146/204, 72%) and digital multiplex quantitative gene expression profiling (DM-GEP; NanoString IO360; n=176/204, 86%). A total of 72% of biopsies were collected at the last relapse prior to enrollment or at the time of enrollment; the remaining samples were collected either at diagnosis or another timepoint prior to enrollment. In the molecular study cohort, 106/204 pts (52%) received Tafa-R2 and 98/204 (48%) Pbo-R2.

Results: The molecular study cohort was representative of the overall R/R FL inMIND population. Preliminary analyses did not reveal significant differences in mutation frequencies or separate cases by time of biopsy collection; therefore, all cases were combined for the analyses. The mutational landscape was consistent with previous reports in FL, with the most frequent nonsynonymous somatic mutations found in KMT2D (76%), CREBBP (73%), TNFRSF14 (35%), BCL2 (31%), PCLO (21%), ARID1A (19%), STAT6 (19%), EP300 (18%), FOXO1 (17%), and EZH2 (16%). A higher rate of TP53 mutations was observed in the Tafa-R2 (n=13/106, 12%) and Pbo-R2 arms (n=9/98, 9%) of inMIND vs the previously untreated advanced FL GLSG2000/BCCA cohorts (n=15/258, 6%) (Pastore, Lancet Oncol 2015; chi-square P=0.05), reflecting the high-risk profile of pts in inMIND. Conversely, the lower frequency of EZH2 mutations in the Tafa-R2 (n=16/106, 15%) and Pbo-R2 (n=16/98, 16%) arms vs untreated cohorts (n=64/258, 25%; chi-square P=0.02) likely reflects the lower relapse risk of pts with EZH2-mutant FL due to the higher efficacy of prior CHOP-based CIT in this subgroup (Passerini, ASH 2025). The increased risk profile of the inMIND molecular study cohort was also reflected by the fraction of pts classified as high risk by the clinicogenetic risk model m7-FLIPI (29% Tafa-R2, 27% Pbo-R2).

In the inMIND molecular study cohort, Tafa-R2 showed increased clinical activity vs Pbo-R2, with higher CR rates (53% vs 48%) and ORR (86% vs 74%), as well as longer median PFS (22.3 vs 15.4 months, HR 0.62 [95% CI: 0.39, 0.98], P=0.04). Tafa-R2 showed activity across molecularly defined high-risk subgroups, including higher ORR in pts with high-risk m7-FLIPI (94% vs 73%) and a trend towards longer PFS (HR 0.77 [95% CI: 0.32, 1.81], P=0.55). Notably, EZH2 mutations were associated with inferior outcomes in the Pbo-R2 arm; ORR in pts with EZH2-mutant FL was 62% vs 77% for EZH2–wild-type (WT) FL. In contrast, in the Tafa-R2 arm, ORR was 94% and 84% in pts with EZH2-mutant and EZH2-WT FL, respectively. In a multivariate analysis, treatment arm (Tafa-R2 vs Pbo-R2) and EZH2 mutation status (mutated vs WT) were each independently associated with PFS (Tafa-R2: HR 0.59 [95% CI: 0.37, 0.94], P=0.03; EZH2 mutated: HR 1.79 [95% CI: 1.02, 3.13], P=0.04). The treatment-by-mutation interaction was not significant (P=0.216), suggesting the treatment effect was consistent across EZH2 subgroups. To better understand the inferior activity of R2 in EZH2-mutant FL, we used DM-GEP data and found that EZH2 mutation status was associated with lower T-cell infiltration, particularly CD8 (P=0.02) and cytotoxic cells (P=0.07). Furthermore, the chemokine ligands CCL5 and CCL22 and chemokine receptor CXCR3 showed a trend of decreased expression in EZH2-mutated cases supporting this observation.

Conclusions: Tafa-R2 consistently demonstrated activity in R/R FL, including in molecularly defined high-risk pt subgroups such as m7-FLIPI and irrespective of EZH2 mutation status. These hypothesis-generating findings warrant validation in larger independent cohorts.
Diana Alvarez Arias: Incyte Corporation - Stock (publicly traded); Incyte Corporation - Current Employment